Nordic Pharma will spotlight its dry eye therapy, Lacrifill Canalicular Gel, at the upcoming American Academy of Ophthalmology (AAO) annual meeting, October 18-20 in Orlando. The company will also present recently published patient data and patient experience study results.

“Eye care professionals attend AAO to learn about ophthalmic innovations benefiting patients, so being able to share that 98.11% of first-time and repeat Lacrifill Canalicular Gel patients surveyed responded ‘yes’ when asked if they will come back in the future for another dose of Lacrifill Canalicular Gel is really exciting,” said Jai Parekh, MD, MBA, Chief Commercial Officer of Eye Care U.S. “We are continually focused on providing data and educational opportunities showing the impact Lacrifill Canalicular Gel has on patients and practices.”

As part of its ongoing educational initiatives, Vance Thompson, MD; Kayla Karpuk, OD; and Mark Packer, MD, have been invited as collaborating authors for an upcoming “Critical Perspectives” article on lacrimal occlusion in the setting of cataract and refractive surgery, to appear in Expert Review of Ophthalmology.

“Dry eye disease can influence preoperative planning, surgical outcomes, postoperative recovery, satisfaction, and quality of life in patients undergoing premium cataract or refractive surgery," Dr. Thompson said. "Lacrifill fills a niche because it is indicated for up to six months of use, so it can be used preoperatively to optimize the ocular surface and maintain a benefit postoperatively.”

Nordic Pharma will again serve as Premier Sponsor of the Women in Ophthalmology (WIO) Awards Ceremony & Networking Reception, held Saturday, October 18 at 5:30 p.m. at AAO. Conference attendees are invited to visit booth #1401 for injection demonstration sessions and to place orders for Lacrifill Canalicular Gel.